Treviño-Alvarez Andrés M, Gluck Marci E, McElroy Susan L, Cuellar-Barboza Alfredo B
Department of Psychiatry, University Hospital and School of Medicine, Universidad Autonoma de Nuevo Leon, Monterrey 64460, NL, Mexico.
Department of Psychiatry and Psychology, Mayo Clinic Arizona, Phoenix, AZ 85054, USA.
Brain Sci. 2024 Aug 21;14(8):841. doi: 10.3390/brainsci14080841.
Major depressive disorder (MDD) and obesity have a complex bidirectional relationship. However, most studies do not assess increased appetite or weight as a depressive symptom due to limitations in rating scales. Here we aimed to analyze frequently employed depressive-symptom scales and discuss the relevance of weight and appetite assessment items. To elaborate this perspective, we searched for validated questionnaires and scales evaluating depressive symptoms in English. We analyzed appetite and weight items from 20 depressive-symptoms rating scales. Only 8 of 20 rating scales assessed for increased weight or appetite. The scales reported in the literature as the most employed in antidepressants efficacy trials do not assess increased appetite or weight. The current use of rating scales limits our understanding of the relationship between MDD, antidepressants, and obesity. It is necessary to improve our weight and appetite measurements in MDD to clarify the respective impact of depressive symptoms and antidepressants on weight change.
重度抑郁症(MDD)与肥胖存在复杂的双向关系。然而,由于评定量表存在局限性,大多数研究并未将食欲增加或体重增加评估为抑郁症状。在此,我们旨在分析常用的抑郁症状量表,并探讨体重和食欲评估项目的相关性。为详细阐述这一观点,我们检索了经验证的英文问卷和量表,以评估抑郁症状。我们分析了20种抑郁症状评定量表中的食欲和体重项目。20种评定量表中仅有8种评估了体重增加或食欲增加情况。文献中报道的在抗抑郁药疗效试验中使用最多的量表并未评估食欲增加或体重增加情况。当前评定量表的使用限制了我们对MDD、抗抑郁药与肥胖之间关系的理解。有必要改进我们对MDD患者体重和食欲的测量方法,以阐明抑郁症状和抗抑郁药对体重变化的各自影响。